Johnson & Johnson (JNJ) Other Non-Current Liabilities (2009 - 2026)
Johnson & Johnson (JNJ) posted Other Non-Current Liabilities of $486.0 million for Q1 2026, little changed sequentially from $486.0 million in Q4 2025, and down 60.52% YoY from $1.2 billion in Q1 2025.
Johnson & Johnson (JNJ) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Other Non-Current Liabilities data on file, last reported at $486.0 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 60.52% year-over-year to $486.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $486.0 million (down 60.52% YoY) and the FY2025 annual result came in at $486.0 million, down 60.07% from the prior year.
- Other Non-Current Liabilities was little changed at $486.0 million in Q1 2026 per JNJ's latest filing, from $486.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $10.3 billion in Q2 2025, with the low at $486.0 million in Q2 2022.
- Average Other Non-Current Liabilities over 5 years is $1.9 billion, with a median of $1.1 billion recorded in 2023.
- Year-over-year, Other Non-Current Liabilities surged 722.36% in 2025 and tumbled 60.52% in 2026.
- Johnson & Johnson's Other Non-Current Liabilities stood at $525.0 million in 2022, then surged by 108.0% to $1.1 billion in 2023, then grew by 11.45% to $1.2 billion in 2024, then sank by 60.07% to $486.0 million in 2025, then changed by 0.0% to $486.0 million in 2026.
- Business Quant data shows JNJ's Other Non-Current Liabilities at $486.0 million in Q1 2026, $486.0 million in Q4 2025, and $9.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 486.00 Mn |
| Dec 28, 2025 | 486.00 Mn |
| Sep 28, 2025 | 9.93 Bn |
| Jun 29, 2025 | 10.26 Bn |
| Mar 30, 2025 | 1.23 Bn |
| Dec 29, 2024 | 1.22 Bn |
| Sep 29, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.11 Bn |
| Dec 31, 2023 | 1.09 Bn |
| Oct 1, 2023 | 1.18 Bn |
| Jul 2, 2023 | 1.14 Bn |
| Apr 2, 2023 | 1.14 Bn |
| Jan 1, 2023 | 1.12 Bn |
| Oct 2, 2022 | 525.00 Mn |
| Jul 3, 2022 | 536.00 Mn |
| Apr 3, 2022 | 486.00 Mn |
| Jan 2, 2022 | 533.00 Mn |
| Oct 3, 2021 | 613.00 Mn |
| Jul 4, 2021 | 593.00 Mn |